clinical trial · NCT06276556
Extension Study of ABP-671 in Participants With Gout
Atom Therapeutics Co., Ltd·phase3·terminated·n = 43
GoutABP-671Allopurinol
brief summary
The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).
started
Apr 22, 2024
primary completion
Sep 5, 2024
completion
Sep 5, 2024
last updated
Jul 16, 2025
official title
A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol